Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCarey, Lisa
dc.contributor.authorLoirat, Delphine
dc.contributor.authorPunie, Kevin
dc.contributor.authorBardia, Aditya
dc.contributor.authorDieras, Veronique
dc.contributor.authorDalenc, Florence
dc.contributor.authorCortés Castan, Javier
dc.date.accessioned2022-09-09T07:45:33Z
dc.date.available2022-09-09T07:45:33Z
dc.date.issued2022-06-09
dc.identifier.citationCarey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022 Jun 9;8:72.
dc.identifier.issn2374-4677
dc.identifier.urihttp://hdl.handle.net/11351/8091
dc.descriptionBreast cancer; Second-line treatment
dc.description.abstractPatients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician’s choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22–0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28–0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNPJ Breast Cancer;8
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Tractament
dc.subjectAnticossos monoclonals - Ús terapèutic
dc.subject.meshTriple Negative Breast Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshImmunoconjugates
dc.titleSacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41523-022-00439-5
dc.subject.decsneoplasias de mama triple negativos
dc.subject.decs/farmacoterapia
dc.subject.decsinmunoconjugados
dc.relation.publishversionhttps://doi.org/10.1038/s41523-022-00439-5
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Carey LA] University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. [Loirat D] Medical Oncology Department and D3i, Institut Curie, Paris, France. [Punie K] Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. [Bardia A] Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. [Diéras V] Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. [Dalenc F] Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. [Cortés J] International Breast Cancer Center, Quirón Group, Barcelona, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid. Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35680967
dc.identifier.wos000809031400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record